Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC-are we making progress?

被引：2
|
作者：
Fenchel, Klaus [1 ,2 ]
Dale, Stephen P. [3 ]
Dempke, Wolfram C. M. [3 ,4 ]
机构：
[1] Med Sch Hamburg MSH, Hamburg, Germany
[2] Praxisklin Saalfeld Saale, Saalfeld, Germany
[3] Kyowa Kirin Pharmaceut Dev Ltd, Galashiels, Scotland
[4] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Haematol & Oncol, Munich, Germany
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2016年 / 5卷 / 04期
关键词：
RANDOMIZED CONTROLLED-TRIAL; MUTANT LUNG-CANCER; 1ST-LINE TREATMENT; PHASE-3; TRIAL; DOUBLE-BLIND; OPEN-LABEL; CHEMOTHERAPY; GEFITINIB; AFATINIB; ADENOCARCINOMA;
D O I：
10.21037/tlcr.2016.07.01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：373 / 376
页数：4
相关论文
共 50 条
  • [1] Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancerthe Holy Grail in cancer treatment?
    Sellmann, Ludger
    Fenchel, Klaus
    Dempke, Wolfram C. M.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (03) : 223 - 227
  • [2] Different genetic profiles of resistant and sensitive patients with EGFR wild type NSCLC undergoing tyrosine kinase inhibitor (TKI) treatment
    Ulivi, P. U.
    Chiadini, E. C.
    Dubini, A. D.
    Calistri, D. C.
    Puccetti, M. P.
    Burgio, M. A. B.
    Delmonte, A. D.
    Verlicchi, A. V.
    Gamboni, A. G.
    Papi, M. P.
    Zoli, W. Z.
    Crino, L. C.
    Dazzi, C. D.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 168 - 168
  • [3] Clinical Outcome Following Change of Tyrosine Kinase Inhibitor (TKI) According to the Detection of an ABL Kinase Mutation
    Palani, Renuka
    Szydlo, Richard M.
    Apperley, Jane F.
    Gerrard, Gareth
    Giles, Chrissy
    Deplano, Simona
    Reid, Alistair
    Foroni, Letizia
    Milojkovic, Dragana
    BLOOD, 2014, 124 (21)
  • [4] Use of FLT PET Imaging to Assess Tyrosine Kinase Inhibitor (TKI) Treatment Response
    Jeraj, R.
    Vanderhoek, M.
    Simoncic, U.
    Perlman, S.
    Alberti, D.
    Wilding, G.
    Liu, G.
    MEDICAL PHYSICS, 2009, 36 (06)
  • [5] Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
    Haznedaroglu, Ibrahim C.
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2014, 6 (01)
  • [6] Treatment of the Sgca-null mouse with a second generation tyrosine kinase inhibitor (TKI)
    Pinol-Jurado, P.
    Suarez-Calvet, X.
    Borrell-Pages, M.
    Fernandez-Simon, E.
    Diaz, V. Lopez
    Gallardo, E.
    Badimon, L.
    Diaz-Manera, J.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S107 - S107
  • [7] TKI258, a novel, multitargeted tyrosine kinase inhibitor for the treatment of breast cancer
    Liu, H.
    Schulz, C. O.
    Regierer, A. C.
    Dieing, A.
    Possinger, K.
    Eucker, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC
    Rosell, R.
    Karachaliou, N.
    Cui, J. J.
    Chaib, I.
    Berenguer, J.
    Bratch, J.
    Li, X.
    Yang, J.
    Drozdowskyj, A.
    Codony Servat, C.
    Codony Servat, J.
    Gimenez-Capitan, A.
    Viteri, S.
    Molina-Vila, M.
    Lopez-Vivanco, G.
    Vergnenegre, A.
    Sanchez-Torres, J. M.
    Provencio, M.
    De Marinis, F.
    Passaro, A.
    Carcereny, E.
    Reguart, N.
    Garcia Campelo, R.
    Ignatius Ou, S.
    Cardona, A.
    Cao, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2230 - S2230
  • [9] Trends in Frontline Treatment and Overall Survival in the Era of Targeted Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
    Vardell, Victoria A.
    Sobieski, Catherine E.
    Tantravahi, Srinivas K.
    BLOOD, 2022, 140 : 6763 - 6764
  • [10] Long Progression Free Survival and Overall Survival in Advanced NSCLC Patients with EGFR Mutation and Complete Response with TKI Treatment
    Macedo-Perez, O.
    Lyra-Gonzalez, I.
    Marroquin-Flores, D.
    Cruz-Rico, G.
    Ramirez-Tirado, L.
    Valdez-Rojas, L.
    Tabares-Nanez, A.
    Gonzales-Nogales, J.
    Arrieta, O.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2087 - S2087
12345